Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465126 | 0.84 | KDM1A (0.44) | KDM1AADRA2ACYP3A4ARDRD2 | |
| SCHEMBL744235 | 0.77 | ADRA2A (0.39) | KDM1AADRA2ACYP3A4ARDRD2 | |
| SCHEMBL730328 | 0.71 | BACE1 (0.40) | CYP3A4BACE1 | |
| SCHEMBL743822 | 0.65 | ADRA2A (0.43) | KDM1AADRA2AARSMN1; SMN2BACE1 | |
| SCHEMBL3465741 | 0.63 | KDM1A (0.46) | KDM1AADRA2ACYP3A4ARDRD2 | |
| SCHEMBL743695 | 0.63 | ADRA2A (0.37) | KDM1AADRA2ACYP3A4DRD2DRD1 | |
| SCHEMBL1495858 | 0.62 | KDM1A (0.53) | KDM1AADRA2ACYP3A4DRD2DRD1 | |
| SCHEMBL19469571 | 0.61 | SMN1; SMN2 (0.56) | KDM1AADRA2ACYP3A4ARSMN1; SMN2 | |
| SCHEMBL19520534 | 0.61 | SMN1; SMN2 (0.56) | KDM1AADRA2ACYP3A4ARSMN1; SMN2 | |
| SCHEMBL19469553 | 0.61 | SMN1; SMN2 (0.56) | KDM1AADRA2ACYP3A4ARSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138179-B2 | Spiro-imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-8138179-B2 | Spiro-imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20090192145-A1 | Spiro-Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192145-A1 | Spiro-Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007116098-A1 | SPIRO-IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192145-A1 | Spiro-Imidazo Compounds | REN, NR3C2, AGTR1 | KDM1A 3697/4885ADRA2A 138/4885CYP3A4 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.